Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance - ATRIPLA®

Bristol-Myers Squibb CompanyBristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (NASDAQ: GILD) today announced an agreement to commercialize ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe for the treatment of virologically suppressed adults with HIV-1 infection, subject to the product's approval by the European Commission. If approved, ATRIPLA would represent the first and only once-daily single tablet regimen for HIV-1 infection in the European Union. The companies expect the European Commission to issue its decision by the end of the year.

Under this agreement, Bristol-Myers Squibb and Gilead share responsibility for commercializing ATRIPLA throughout the European Union and certain other European countries. Gilead will record revenues from future net sales of ATRIPLA in most of the European countries, while Bristol-Myers Squibb will record revenues in most of the European countries at percentages relative to the contribution represented by its individual product.

Bristol-Myers Squibb recently concluded an agreement with Merck & Co., Inc. under which Merck granted Bristol-Myers Squibb rights to co-commercialize ATRIPLA with Gilead in all of the European Union and certain other European countries. Previously, Merck had the exclusive right to market any product containing efavirenz (a component of ATRIPLA) in all European countries other than the United Kingdom, Germany, France, Italy, Spain and the Republic of Ireland.

Efavirenz is marketed by Bristol-Myers Squibb under the tradename SUSTIVA® in the United States, Canada and six major countries of the European Union. Efavirenz will continue to be commercialized by Merck & Co, Inc, through its affiliate Merck Sharp & Dohme (MSD) Limited under the tradename STOCRIN® in all other countries within the European Union and many countries outside of the United States. Emtricitabine and tenofovir disoproxil fumarate are commercialized by Gilead under the tradenames Emtriva® and Viread®, respectively, and are commonly prescribed together as a once-daily, fixed-dose tablet, marketed under the tradename Truvada® for use as part of combination therapy.

ATRIPLA is currently sold in the United States and Canada through a joint venture between Bristol-Myers Squibb and Gilead. ATRIPLA was approved by the U.S. Food and Drug Administration (FDA) in July 2006 and by Health Canada in October 2007. Gilead and Merck previously announced a collaboration to distribute ATRIPLA in developing countries.

For complete U.S. prescribing information, including Boxed WARNINGS, for ATRIPLA, visit http://www.atripla.com. For complete prescribing information for SUSTIVA, visit http://www.bms.com. For complete U.S. prescribing information for Truvada, Viread and Emtriva, including Boxed WARNINGS, visit visit www.gilead.com.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company. Visit Bristol-Myers Squibb on the World Wide Web at www.bms.com.

About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. Visit Gilead on the World Wide Web at www.gilead.com.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Study links widely-used drug azathioprine to skin …

A drug used to treat inflammatory bowel disease, arthritis and vasculitis as well as to prevent organ rejection in transplant patients has been identified as an important...

Pfizer and Astellas amend clinical research protoc…

Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced amendments to the protocols for two registratio...